GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chong Kun Dang Pharmaceutical 185750.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

62,300

-1.11%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

13 analysts, 1 Feb 2026. The analysts' own views, not ours.

  • 4Strong buy
  • 8Buy
  • 1Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Feb 2026. Not our view.

Average target 115,260

Low
101,000
Average
115,260
Median
112,200
High
141,750

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028
Revenue₩1.86trn₩1.95trn₩2.04trn
Revenue, highest₩1.87trn₩2.00trn₩2.07trn
Revenue, lowest₩1.86trn₩1.94trn₩2.04trn
Earnings per share5010.506098.756817.25
Earnings per share, highest5356.066647.396930.28
Earnings per share, lowest4790.646073.736789.28
Analysts362

Earnings against forecasts

Earnings per share by fiscal quarter

Q2 2026Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023
Forecast2544.001732.691246.581431.211824.641656.281134.26
Reported1517.38894.00273.001643.814007.621917.146162.86
Difference-40.4%-48.4%-78.1%+14.9%+119.6%+15.7%+443.3%

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

4 / 10

Revenue growth 11.1% a year over 10 years. Return on equity 7.7%.

Model fair value

60,588.81

From earnings 60,588.81, from revenue 80,243.07.

Piotroski score

3 / 9

A nine-point test of financial strength, for 31 Dec 2025.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.